BOT - Anything but charting, page-16130

Just received notification from the International Hyperhidrosis Society their blog on latest research which includes this snippet on Sofdra


Sofdra™So far this year, key articles have been published in medical journals about the newest hyperhidrosis treatment on the market: Sofdra—a topical gel also known as sofpironium bromide. Importantly, three of our co-founders and members of the Board of Directors published pooled safety and efficacy data on Sofdra in the Journal of the American Academy of Dermatology, based on two randomized, double-blind, controlled clinical trials. The combined trials included 353 people in the treatment groups and 348 in the control (placebo) groups. Patients as young as nine years old participated, but most were adults who had suffered from underarm excessive sweating for about 14 years. Analysis of the combined results, say the authors, shows “statistically significant and clinically meaningful” improvements in underarm excessive sweating (primary axillary hyperhidrosis) from Sofdra treatment, based on both patient-reported outcomes and objective sweat measurements. Using a recognized scale for measuring excessive sweating severity (the Hyperhidrosis Disease Severity Scale), the data shows that more than 56% of patients had a 2-point improvement in their underarm sweating severity when using Sofdra, compared to 37% using the placebo. In terms of measured sweat volume (how much sweat output a person had), patients using Sofdra experienced a 138mg decrease in sweating, while those using the placebo decreased their sweating by 114mg. The authors note that, while the placebo (a gel without Sofdra’s active ingredient) gave patients some results in terms of patient-reported outcomes and reduced sweating, this was expected because the gel “has emollient properties and can affect skin function. Additionally, patients with hyperhidrosis experience anxiety about their sweating, and this anxiety could trigger further sweating whereas the hope of receiving treatment could reduce anxiety and anxiety-produced sweating.”No serious side effects from Sofdra were reported. The most common side effects were dry mouth, underarm pain, blurred vision, dilated pupils of the eyes, underarm redness, and swelling and irritation of underarm skin. In other Sofdra news, in a letter to the editors of the journal Annals of Medicine and Surgery, eight authors reiterate the usefulness of Sofdra to treat underarm excessive sweating noting its targeted nature (localized to the skin of the underarms), its effectiveness, and its more limited side effects (as compared to those of oral medications.) Their call to action is that more people should be made aware of this treatment option and that it should be made more affordable and accessible. Cost effectiveness studies of Sofdra compared to other treatments, they say, could be especially helpful.